Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

The weight loss jab Mounjaro will soon be made available to nearly a quarter of a million NHS patients, according to ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...

While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second.

After Wegovy and Ozempic by pharmaceutical company Novo Nordisk, Netherlands residents will soon also have access to another ...

With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...

A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s ...

NICE has opened a consultation on the possible mass rollout of tirzepatide to millions of people in England over the next decade.

The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...

GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list. ...